A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,605,690

Introduction

United States Patent 5,605,690 (hereafter "the patent") was granted on February 25, 1997, to address innovations in drug delivery systems, particularly concerning sustained-release pharmaceutical formulations. This patent has significant implications within the pharmaceutical industry, notably in controlled-release therapeutics, and has influenced subsequent patent filings and research efforts. This analysis dissects the patent's claims, scope, validity, and overlaps within the existing patent landscape, providing insights critical for stakeholders including innovators, patent practitioners, and legal professionals.

Patent Overview and Scope of Claims

Key Features of the Patent

The patent primarily relates to a drug delivery system that facilitates controlled or sustained release of active pharmaceutical ingredients (APIs). It emphasizes a matrix-based formulation, often comprising polymers capable of modulating drug release over an extended period.

It discloses a matrix comprising a polymer and an active ingredient, with specific parameters for the polymer's composition, molecular weight, and formulation process to achieve desired release profiles. Moreover, the patent encompasses methods of manufacturing such systems and their use in delivering specific APIs.

Claim Structure and Critical Elements

The claims of US 5,605,690 are mainly directed towards:

Claim 1: A sustained-release pharmaceutical composition comprising a particular polymer matrix in conjunction with an active pharmaceutical ingredient. This independent claim lays out the essential components, emphasizing polymer characteristics—such as molecular weight, polymer type, and drug-polymer ratios.
Dependent Claims: Narrow the scope in terms of polymer type (e.g., polyethylene oxide or ethylene-vinyl acetate copolymers), specific drug molecules (e.g., opioids, NSAIDs), and manufacturing procedures.
Method Claims: Cover methods of preparing the matrix or administering the composition for therapeutic effect.

The core inventive concept centers on controlled release via specific polymer matrices to optimize drug release kinetics, enhancing therapeutic efficacy and compliance.

Critical Analysis of the Claims

Strengths of the Patent Claims

Robust Scope for Fundamental Technologies: The broad independent claim secures a wide territory for sustained-release formulations employing certain classes of polymers, offering a protective barrier against competing formulations that utilize similar matrices.
Method Claims Covering Manufacturing Processes: These claims can prevent reverse engineering or process infringement, adding strategic value.
Technical Specificity: Parameters such as polymer molecular weight and composition details offer clarity, facilitating enforcement and licensing negotiations.

Limitations and Potential Challenges

Scope and Patentability of the Broad Claims: The broadness of Claim 1 could face validity challenges based on prior art disclosures that describe similar polymer-drug matrices predating 1997, such as earlier sustained-release systems (e.g., the osmotic pump or matrix systems described in prior patents like US 4,735,840).
Obviousness Concerns: The use of certain polymers for sustained release was well-known in the art. The patent’s claims might be challenged as an obvious modification of existing formulations if prior art references demonstrate similar compositions.
Insufficient Distinctiveness: The patent’s claims are heavily reliant on specific polymer parameters; if these are not sufficiently inventive over existing technologies, the patent could be vulnerable to invalidation.

Validity and Enforcement Considerations

Evaluating patent validity requires scrutinizing prior art, including earlier patents, scientific literature, and regulatory filings. The patent’s claims are cautious but broad enough to face potential validity challenges, especially in jurisdictions with a rigorous obviousness standard.

Enforcement would necessitate demonstrating that infringing products employ identical or substantially similar polymer matrices and manufacturing processes. Given the prevalence of polymer-based controlled-release systems, infringement cases could be complex, involving detailed technical analyses.

The Patent Landscape: Precedents and Related Patents

Pre-Existing Patents and Publications

Prior to the 1997 patent, the pharmaceutical industry relied on various controlled-release technologies, including:

Matrix systems using hydrophilic polymers (e.g., US 4,235,236, 1980): Early work on hydrophilic matrices laid groundwork for later innovations.
Osmotic pump systems (e.g., US 4,198,264, 1980): These deliver drugs via osmotic-driven mechanisms, which differ from matrix-based systems but target sustained release.
US 4,735,840 (1988): Disclosures on polymer-based matrices complement the scope of the 5,605,690 patent, potentially serving as prior art.

Subsequent Patents and Innovations

Post-1997, numerous patents have built upon or around the claims of US 5,605,690, particularly as new polymers, formulation techniques, and delivery devices emerged:

Polymer Innovations: Patents such as US 6,699,864 (2004) explore novel copolymers for enhanced drug release profiles.
Combination Devices: Patent filings describe multi-layered systems or multilayer matrices that might challenge or circumvent the scope of the patent's claims.
Biotech and Nanoscale Delivery Systems: Advances such as nanoparticle carriers and composite matrices have shifted some innovation away from the scope of the 1997 patent, yet certain core principles still remain relevant.

Patent Landscape and Freedom-to-Operate Analysis

The patent landscape surrounding sustained-release systems is complex, with overlapping patents covering:

Specific polymer compositions.
Delivery methods.
Manufacturing processes.
Therapeutic applications.

A thorough freedom-to-operate (FTO) analysis must consider:

The extent of the patent's claim discrimination.
Pending patent applications targeting similar technologies.
Unique formulation aspects of competitors' products.

Legal and Commercial Implications

While US 5,605,690 provided an early strong patent position in polymer-based sustained-release formulations, the crowded patent landscape and evolving technologies imply that enforcement or leveraging this patent requires careful navigation of prior art and potential licensing agreements.

Concluding Remarks

The patent claims of US 5,605,690 articulate a foundational approach to controlled-release pharmaceutical compositions utilizing polymer matrices. Its strength lies in broad scope, which historically fostered innovation but also invites validity challenges due to the prior art landscape. The patent shaped subsequent developments in sustained-release technology, though its enforceability hinges on precise technical nuances and the specifics of formulations and manufacturing processes.

In the current landscape, innovations have shifted towards advanced polymers, nanotechnology, and multi-modal delivery systems. Nevertheless, the principles embodied in US 5,605,690 remain relevant for ongoing research and development in controlled-release pharmaceuticals.

Key Takeaways

Patent Breadth and Validity: While the patent protected core technology, its broad claims are susceptible to invalidation through prior art, emphasizing the importance of precise claim drafting and proactive patent landscaping.
Landscape Navigation is Essential: The patent landscape for sustained-release systems is crowded, requiring careful FTO analysis before product development or licensing.
Continued Innovation is Necessary: As newer delivery mechanisms emerge, reliance solely on the technology within US 5,605,690 may be insufficient; continuous innovation is critical to maintain competitive advantage.
Strategic Patent Positioning: Companies should consider patenting incremental modifications and formulations to extend patent life and coverage in this space.
Legal Vigilance: Enforcement efforts should be grounded in detailed technical analyses to avoid frivolous litigation and ensure robust infringement claims.

FAQs

1. Can I develop a sustained-release formulation using polymers similar to those in US 5,605,690 without infringing?
Developing a formulation with different polymers or significantly altering the composition or manufacturing process may circumvent infringement. However, detailed freedom-to-operate analyses and potentially legal counsel are essential before proceeding.

2. How does prior art affect the validity of US 5,605,690?
Prior art that discloses similar controlled-release matrices, especially before the patent’s filing date, could render the patent invalid for lack of novelty or inventive step.

3. Are the claims of US 5,605,690 still enforceable today?
The patent expired in 2017, so enforcement is no longer applicable. However, its claims previously provided broad protection for specific controlled-release formulations.

4. What are the risks of patent infringement in developing new controlled-release formulations?
Risks include potential infringement if formulations employ similar polymers and processing techniques protected by active patents. Rigorous patent clearance searches are mandatory.

5. How has the patent landscape evolved since the issuance of US 5,605,690?
Post-1997, numerous patents have been filed covering novel polymers, delivery devices, and combination therapies, expanding and sometimes overlapping with the original scope, highlighting the importance of continuous patent monitoring.

Sources

[1] United States Patent 5,605,690. "Controlled release pharmaceutical formulations," granted 1997.
[2] Prior art disclosures including US 4,235,236 (1979), US 4,735,840 (1988).
[3] Industry reviews on sustained-release technologies, see A. K. Chaturvedi, "Controlled Release Drug Delivery Systems," 2012.
[4] Regulatory filings and patent applications related to controlled-release formulations.

Title:	Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor
Abstract:	A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
Inventor(s):	Jacobs; Cindy A. (Seattle, WA), Smith; Craig A. (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	08/385,229
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,605,690 Introduction United States Patent 5,605,690 (hereafter "the patent") was granted on February 25, 1997, to address innovations in drug delivery systems, particularly concerning sustained-release pharmaceutical formulations. This patent has significant implications within the pharmaceutical industry, notably in controlled-release therapeutics, and has influenced subsequent patent filings and research efforts. This analysis dissects the patent's claims, scope, validity, and overlaps within the existing patent landscape, providing insights critical for stakeholders including innovators, patent practitioners, and legal professionals. Patent Overview and Scope of Claims Key Features of the Patent The patent primarily relates to a drug delivery system that facilitates controlled or sustained release of active pharmaceutical ingredients (APIs). It emphasizes a matrix-based formulation, often comprising polymers capable of modulating drug release over an extended period. It discloses a matrix comprising a polymer and an active ingredient, with specific parameters for the polymer's composition, molecular weight, and formulation process to achieve desired release profiles. Moreover, the patent encompasses methods of manufacturing such systems and their use in delivering specific APIs. Claim Structure and Critical Elements The claims of US 5,605,690 are mainly directed towards: Claim 1: A sustained-release pharmaceutical composition comprising a particular polymer matrix in conjunction with an active pharmaceutical ingredient. This independent claim lays out the essential components, emphasizing polymer characteristics—such as molecular weight, polymer type, and drug-polymer ratios. Dependent Claims: Narrow the scope in terms of polymer type (e.g., polyethylene oxide or ethylene-vinyl acetate copolymers), specific drug molecules (e.g., opioids, NSAIDs), and manufacturing procedures. Method Claims: Cover methods of preparing the matrix or administering the composition for therapeutic effect. The core inventive concept centers on controlled release via specific polymer matrices to optimize drug release kinetics, enhancing therapeutic efficacy and compliance. Critical Analysis of the Claims Strengths of the Patent Claims Robust Scope for Fundamental Technologies: The broad independent claim secures a wide territory for sustained-release formulations employing certain classes of polymers, offering a protective barrier against competing formulations that utilize similar matrices. Method Claims Covering Manufacturing Processes: These claims can prevent reverse engineering or process infringement, adding strategic value. Technical Specificity: Parameters such as polymer molecular weight and composition details offer clarity, facilitating enforcement and licensing negotiations. Limitations and Potential Challenges Scope and Patentability of the Broad Claims: The broadness of Claim 1 could face validity challenges based on prior art disclosures that describe similar polymer-drug matrices predating 1997, such as earlier sustained-release systems (e.g., the osmotic pump or matrix systems described in prior patents like US 4,735,840). Obviousness Concerns: The use of certain polymers for sustained release was well-known in the art. The patent’s claims might be challenged as an obvious modification of existing formulations if prior art references demonstrate similar compositions. Insufficient Distinctiveness: The patent’s claims are heavily reliant on specific polymer parameters; if these are not sufficiently inventive over existing technologies, the patent could be vulnerable to invalidation. Validity and Enforcement Considerations Evaluating patent validity requires scrutinizing prior art, including earlier patents, scientific literature, and regulatory filings. The patent’s claims are cautious but broad enough to face potential validity challenges, especially in jurisdictions with a rigorous obviousness standard. Enforcement would necessitate demonstrating that infringing products employ identical or substantially similar polymer matrices and manufacturing processes. Given the prevalence of polymer-based controlled-release systems, infringement cases could be complex, involving detailed technical analyses. The Patent Landscape: Precedents and Related Patents Pre-Existing Patents and Publications Prior to the 1997 patent, the pharmaceutical industry relied on various controlled-release technologies, including: Matrix systems using hydrophilic polymers (e.g., US 4,235,236, 1980): Early work on hydrophilic matrices laid groundwork for later innovations. Osmotic pump systems (e.g., US 4,198,264, 1980): These deliver drugs via osmotic-driven mechanisms, which differ from matrix-based systems but target sustained release. US 4,735,840 (1988): Disclosures on polymer-based matrices complement the scope of the 5,605,690 patent, potentially serving as prior art. Subsequent Patents and Innovations Post-1997, numerous patents have built upon or around the claims of US 5,605,690, particularly as new polymers, formulation techniques, and delivery devices emerged: Polymer Innovations: Patents such as US 6,699,864 (2004) explore novel copolymers for enhanced drug release profiles. Combination Devices: Patent filings describe multi-layered systems or multilayer matrices that might challenge or circumvent the scope of the patent's claims. Biotech and Nanoscale Delivery Systems: Advances such as nanoparticle carriers and composite matrices have shifted some innovation away from the scope of the 1997 patent, yet certain core principles still remain relevant. Patent Landscape and Freedom-to-Operate Analysis The patent landscape surrounding sustained-release systems is complex, with overlapping patents covering: Specific polymer compositions. Delivery methods. Manufacturing processes. Therapeutic applications. A thorough freedom-to-operate (FTO) analysis must consider: The extent of the patent's claim discrimination. Pending patent applications targeting similar technologies. Unique formulation aspects of competitors' products. Legal and Commercial Implications While US 5,605,690 provided an early strong patent position in polymer-based sustained-release formulations, the crowded patent landscape and evolving technologies imply that enforcement or leveraging this patent requires careful navigation of prior art and potential licensing agreements. Concluding Remarks The patent claims of US 5,605,690 articulate a foundational approach to controlled-release pharmaceutical compositions utilizing polymer matrices. Its strength lies in broad scope, which historically fostered innovation but also invites validity challenges due to the prior art landscape. The patent shaped subsequent developments in sustained-release technology, though its enforceability hinges on precise technical nuances and the specifics of formulations and manufacturing processes. In the current landscape, innovations have shifted towards advanced polymers, nanotechnology, and multi-modal delivery systems. Nevertheless, the principles embodied in US 5,605,690 remain relevant for ongoing research and development in controlled-release pharmaceuticals. Key Takeaways Patent Breadth and Validity: While the patent protected core technology, its broad claims are susceptible to invalidation through prior art, emphasizing the importance of precise claim drafting and proactive patent landscaping. Landscape Navigation is Essential: The patent landscape for sustained-release systems is crowded, requiring careful FTO analysis before product development or licensing. Continued Innovation is Necessary: As newer delivery mechanisms emerge, reliance solely on the technology within US 5,605,690 may be insufficient; continuous innovation is critical to maintain competitive advantage. Strategic Patent Positioning: Companies should consider patenting incremental modifications and formulations to extend patent life and coverage in this space. Legal Vigilance: Enforcement efforts should be grounded in detailed technical analyses to avoid frivolous litigation and ensure robust infringement claims. FAQs 1. Can I develop a sustained-release formulation using polymers similar to those in US 5,605,690 without infringing? Developing a formulation with different polymers or significantly altering the composition or manufacturing process may circumvent infringement. However, detailed freedom-to-operate analyses and potentially legal counsel are essential before proceeding. 2. How does prior art affect the validity of US 5,605,690? Prior art that discloses similar controlled-release matrices, especially before the patent’s filing date, could render the patent invalid for lack of novelty or inventive step. 3. Are the claims of US 5,605,690 still enforceable today? The patent expired in 2017, so enforcement is no longer applicable. However, its claims previously provided broad protection for specific controlled-release formulations. 4. What are the risks of patent infringement in developing new controlled-release formulations? Risks include potential infringement if formulations employ similar polymers and processing techniques protected by active patents. Rigorous patent clearance searches are mandatory. 5. How has the patent landscape evolved since the issuance of US 5,605,690? Post-1997, numerous patents have been filed covering novel polymers, delivery devices, and combination therapies, expanding and sometimes overlapping with the original scope, highlighting the importance of continuous patent monitoring. Sources [1] United States Patent 5,605,690. "Controlled release pharmaceutical formulations," granted 1997. [2] Prior art disclosures including US 4,235,236 (1979), US 4,735,840 (1988). [3] Industry reviews on sustained-release technologies, see A. K. Chaturvedi, "Controlled Release Drug Delivery Systems," 2012. [4] Regulatory filings and patent applications related to controlled-release formulations. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	5,605,690	2015-02-08
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	5,605,690	2015-02-08
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	5,605,690	2015-02-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	907072	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9406476	⤷ Start Trial
World Intellectual Property Organization (WIPO)	9319777	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 5,605,690

Summary for Patent: 5,605,690